A
Alcista
Alcista · 25%IONS
$34.91
Precio del escenario
$43.420
+0.495 (+1.14%)Al cierre
Loading chart…
- Máximo
- 43.920
- Apertura
- 43.000
- Precio medio ponderado por volumen
- 43.37
- Volumen
- 3.20M
- Capitalización
- 6.89B
- Mínimo
- 42.760
- Importe
- 138.67M
- EV/EBITDA, TTM
- -18.84
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Análisis de IA of Ionis Pharmaceuticals Inc (IONS)
MantenerIonis Pharmaceuticals is not a good buy right now due to a current price of $42.93, which is down 46.12% year-to-date, and an RSI of 39.846 indicating oversold conditions. The forward P/E ratio is extremely high at 90.9091, suggesting that the stock is overvalued relative to its earnings potential. Additionally, the company has faced substantial losses, with a net income loss of $114.646 million in Q2 2026. The main risk is the high forward P/E ratio, which could indicate that the stock is not a good investment at this price point.
Recomendaciones de analistas (15)
+113.43% de potencial alcista
Mantener
5 Comprar
8 Mantener
2 Vender
Actual: 43.42
Mínimo
65.00
Promedio
92.67
Máximo
110.00
JPMorgan
Sobreponderar
$70
2026-09-22
JPMorgan
2026-09-22
Precio objetivo
$70
Sobreponderar
Guggenheim
Comprar
$80
2026-09-15
Guggenheim
2026-09-15
Precio objetivo
$80
Comprar
Barclays
Sobreponderar
$85
2026-09-09
Barclays
2026-09-09
Precio objetivo
$85
Sobreponderar
Raymond James
Superar al mercado
$84
2026-09-08
Raymond James
2026-09-08
Precio objetivo
$84
Superar al mercado
Morgan Stanley
Sobreponderar
$104
2026-09-08
Morgan Stanley
2026-09-08
Precio objetivo
$104
Sobreponderar
Métricas de valoración
El PER previsto actual de Ionis Pharmaceuticals Inc (IONS) es 90.91, frente a su media de 5 años de 1.47.
Escenarios de precio de Alphio AI para IONS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con IONS en cartera
Cronología de eventos
Noticias
9.010-23NewsfilterSefaxersen Achieves Significant Proteinuria Reduction in IgAN Patients
- 5.010-22Newsfilter
Ionis Pharmaceuticals Named Top Employer by Science
6.010-22CNBCLatest Rating Changes on Wall Street
2.010-21FoolAlnylam Pharmaceuticals Shares Plunge 40% Amidst Profitability Concerns
- 9.010-21Newsfilter
FDA Approves Hibsago for Chronic Hepatitis B Treatment
Preguntas frecuentes sobre IONS, respondidas por Alphio AI
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Ionis Pharmaceuticals is not a good buy right now due to a current price of $42.93, which is down 46.12% year-to-date, and an RSI of 39.846 indicating oversold conditions. The forward P/E ratio is extremely high at 90.9091, suggesting that the stock is overvalued relative to its earnings potential. Additionally, the company has faced substantial losses, with a net income loss of $114.646 million in Q2 2026. The main risk is the high forward P/E ratio, which could indicate that the stock is not a good investment at this price point.
15 analysts cover IONS: 5 rate it Buy, 8 Hold and 2 Sell. The average price target is 92.67.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.